Reviewing Clearmind Medicine (NASDAQ:CMND) & Sonnet BioTherapeutics (NASDAQ:SONN)

Sonnet BioTherapeutics (NASDAQ:SONN) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Valuation and Earnings

This table compares Sonnet BioTherapeutics and Clearmind Medicine”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonnet BioTherapeutics	$55,881.00	348.06	-$18.83 million	N/A	N/A
Clearmind Medicine	N/A	N/A	-$8.62 million	N/A	N/A

Clearmind Medicine has lower revenue, but higher earnings than Sonnet BioTherapeutics.

Profitability

This table compares Sonnet BioTherapeutics and Clearmind Medicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sonnet BioTherapeutics	N/A	-398.45%	-142.16%
Clearmind Medicine	N/A	-238.73%	-102.10%

Risk & Volatility

Sonnet BioTherapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Clearmind Medicine has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.

Insider & Institutional Ownership

9.4% of Sonnet BioTherapeutics shares are held by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are held by institutional investors. 2.0% of Sonnet BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Sonnet BioTherapeutics and Clearmind Medicine, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonnet BioTherapeutics	0	0	2	0	3.00
Clearmind Medicine	0	0	0	0	N/A

Sonnet BioTherapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 380.00%. Given Sonnet BioTherapeutics’ higher probable upside, equities analysts clearly believe Sonnet BioTherapeutics is more favorable than Clearmind Medicine.

Summary

Clearmind Medicine beats Sonnet BioTherapeutics on 5 of the 9 factors compared between the two stocks.

About Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

About Clearmind Medicine

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.